Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS -mutated metastatic colorectal cancer
-
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia)
;
Cervantes, Andrés (Universitat de València. Biomedical Research Institute) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Roselló, Susana (Universitat de València. Biomedical Research Institute) ;
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Tejpar, Sabine (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Prenen, H. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Martinelli, E. (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Troiani, T. (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Laffranchi, B. (Merck Serono SA) ;
Jego, V (Merck Serono SA) ;
von Richter, O.. (Merck KGaA) ;
Ciardiello, Fortunato (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Universitat Autònoma de Barcelona
visitante ::
identificación
Subscribirse to this discussion. You will then receive all new comments by email.
